Could an antioxidant supplement boost brain function in schizophrenia?
NCT ID NCT06191965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether MitoQ, an antioxidant supplement, can improve thinking and memory in people with early schizophrenia who have signs of mitochondrial dysfunction. Researchers will give 50 participants either MitoQ or a placebo daily for 12 weeks, alongside their usual medications. The goal is to see if MitoQ helps with cognitive skills like attention and problem-solving.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MitoQ (an antioxidant supplement)
What this could lead to
If it works, this could point toward a new way to improve thinking and memory in people with early schizophrenia.
What could go wrong
This is an early-phase trial with only 50 high-risk participants. MitoQ is a supplement, not a proven treatment, and may not improve cognition or symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McLean Hospital
RECRUITINGBelmont, Massachusetts, 02478, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Lausanne
NOT_YET_RECRUITINGLausanne, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Yale School of Medicine
NOT_YET_RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••